Glycemic control during TB treatment among Filipinos [TB0101]
· High TB Incidence in the Philippines:
The Philippines has one of the highest TB incidences globally (539/100,000).
· Diabetes Prevalence: In
2020, 6.5% of Filipino adults were estimated to have diabetes mellitus (DM), as
reported by the International Diabetes Federation.
· Impact of Poor Glycemic Control:
Poor long-term glycemic control, measured by HbA1c, is associated with an
increased risk of TB, severe clinical presentations, and poor TB treatment
outcomes.
· Factors Affecting Glycemic Control:
Individual health status, disease management practices, and the health system
all influence glycemic control in DM patients.
· Central Obesity as a Diabetes Risk
Factor: Central obesity, common in Asian populations, predicts
diabetes and is associated with hyperglycemia and poor glycemic control at TB
treatment onset, which can negatively impact TB outcomes.
· TB and Transient Hyperglycemia:
TB-related inflammation and insulin resistance may cause transient
hyperglycemia, resolving with effective TB treatment and potentially
confounding earlier study findings.
· Glycemic Control Over DM Presence:
The degree of glycemic control may be more critical to TB outcomes than simply
having or not having DM.
· DM Diagnosis Timing and Blood Glucose
Control: Patients diagnosed with DM before starting TB treatment are
more likely to have uncontrolled blood glucose levels during treatment than
those diagnosed with DM at treatment start.
· Transient Hyperglycemia and
Overdiagnosis Risk: One-third of those initially identified as new DM
cases may have only transient hyperglycemia, suggesting that DM screening in TB
programs should confirm diagnoses outside the acute treatment phase.
· Central Obesity and HbA1c Levels:
Among DM patients, those without central obesity had higher HbA1c levels than
centrally obese individuals if diagnosed before TB treatment. Conversely, those
diagnosed at treatment start had higher HbA1c levels if centrally obese.
· DM and TB Advanced Disease Stage:
For TB-DM patients without central obesity, higher HbA1c levels may indicate
advanced disease and metabolic disruption. This could reflect severe disease
stages in TB or both TB and DM.
· Research and Multi-site Collaboration:
Exclusions of patients with fewer HbA1c results and small outcome categories
may introduce bias in studies. Future studies require larger sample sizes (over
1,000 TB-DM patients) to assess the impact of poor glycemic control on TB
outcomes, likely necessitating multi-site collaboration.
Comments
Post a Comment